

Determination of Bosentan in Pharmaceutical Preparations by Linear Sweep, Square Wave and Differential Pulse Voltammetry Methods

Alptug Atila* and Bilal Yilmaz

Department of Analytical Chemistry, Faculty of Pharmacy, Ataturk University, 25240, Erzurum, Turkey.

Abstract

In this study, simple, fast and reliable cyclic voltammetry (CV), linear sweep voltammetry (LSV), square wave voltammetry (SWV) and differential pulse voltammetry (DPV) methods were developed and validated for determination of bosentan in pharmaceutical preparations. The proposed methods were based on electrochemical oxidation of bosentan at platinum electrode in acetonitrile solution containing 0.1 M TBAClO₄. The well-defined oxidation peak was observed at 1.21 V. The calibration curves were linear for bosentan at the concentration range of 5-40 µg/mL for LSV and 5-35 µg/mL for SWV and DPV methods, respectively. Intra- and inter-day precision values for bosentan were less than 4.92, and accuracy (relative error) was better than 6.29%. The mean recovery of bosentan was 100.7% for pharmaceutical preparations. No interference was found from two tablet excipients at the selected assay conditions. Developed methods in this study are accurate, precise and can be easily applied to Tracleer and Diamond tablets as pharmaceutical preparation.

Keywords: Bosentan; Cyclic voltammetry; Linear sweep voltammetry; Square wave voltammetry; Differential pulse voltammetry.

Introduction

Bosentan, (4-*tert*-butyl-*N*-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]), is a competitive oral dual endothelin receptor antagonist which is non-selective for endothelin A and B receptors (Figure 1). Bosentan is being used as an oral drug for the treatment of pulmonary arterial hypertension (1, 2). It has a high protein binding rate (98%), especially to albumin and is rapidly absorbed after oral administration. Its bioavailability is 45-50%. The peak plasma concentration occurs within 3-5 h (3, 4). Bosentan is eliminated mainly by hepatic metabolism which renal elimination occurs for

only 0.9% of the administered dose (5).

It is the first orally active drug approved by United States Food and Drug Administrative as Tracleer (125 mg) for the successful treatment of pulmonary arterial hypertension. Tracleer improves the exercise ability and decreases the rate of clinical worsening in patients with WHO Class III or IV symptoms of pulmonary arterial hypertension, by blocking the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects (6-8). Further Tracleer has been demonstrated to be effective in remodeling the pulmonary vascular tree through several mechanisms including vasodilatation, antifibrotic and antithrombotic actions (9).

An extensive literature survey revealed that there are several HPLC methods for the determination of bosentan monohydrate and

* Corresponding author:

E-mail: alptugatila@yahoo.com




Figure 1. Chemical structure of bosentan.

its metabolite in blood plasma, whereas, there are few other literatures disclosed only for the quantitative determination of bosentan in pharmaceutical formulation samples (10-13).

The reported methods were influenced by interference of endogenous substances and potential loss of drugs in the re-extraction procedure and involving lengthy, tedious and time-consuming plasma sample preparation and extraction processes and requiring a sophisticated and expensive instrumentation.

Bosentan is a new drug. There is not official in any pharmacopoeia. The development of a new method capable of determining drug amount in pharmaceutical dosage forms is important. Electroanalytical techniques have been used for the determination of a wide range of drug compounds with the advantages that there are, in most, instances no need for derivatization and that these techniques are less sensitive to matrix effects than other analytical techniques. Additionally, application of electrochemistry includes the determination of electrode mechanism. Redox properties of drugs can give insights into their metabolic fate or their *in-vivo* redox processes or pharmacological activity (14-17). Despite the analytical importance of the electrochemical behavior and oxidation mechanism of bosentan, no report has been published on the voltammetric study of the electrochemical oxidation of bosentan in nonaqueous media. It is well known that the experimental and instrumental parameters directly affect the electrochemical process and voltammetric response of drugs. Consequently, it would be interest to investigate

the oxidation process of bosentan in aprotic media. Therefore, the goal of this work was the development of new LSV, SWV and DPV methods for the direct determination of bosentan in pharmaceutical preparations without any time-consuming extraction or evaporation steps prior to drug assay. This paper describes fully validated simple, rapid, selective and sensitive procedures for the determination of bosentan employing LSV, SWV and DPV methods the platinum disc electrode. Besides, the methods were successfully applied for the quality control of two commercial bosentan tablets form to quantify the drug and to check the formulation content uniformity.

Experimental

Chemical and reagents

Bosentan was obtained from Actelion Pharmaceuticals (Allschwil, Switzerland). Acetonitrile (Fluka for HPLC analysis) was purified by drying with calcium hydride, followed by distillation from phosphorus pentoxide. After purification in order to eliminate its water content as much as possible, it was kept over molecular sieves (3Å, Merck). Tetrabutylammonium perchlorate (TBAClO₄) were purchased from Fluka and used as received without further purification. Tracleer and Diamond tablets (125 mg bosentan) were obtained from pharmacy (Erzurum, Turkey).

Electrochemical instrumentation

Electrochemical experiments were

performed on a Gamry Potentiostat Interface 1000 controlled with software PHE 200 and PV 220. All measurements were carried out in a single-compartment electrochemical cell with a standard three-electrode arrangement. A platinum disk with an area of 0.72 cm² and a platinum wire were used as the working and the counter electrodes, respectively. The working electrode was successively polished with 1.0, 0.3 and 0.05 μm alumina slurries (Buehler) on microcloth pads (Buehler). After each polishing, the electrode was washed with water and sonicated for 10 min in acetonitrile. Then, it was immersed into a hot piranha solution (3:1, H₂SO₄, 30% H₂O₂) for 10 min, and rinsed copiously with water. Caution: Piranha is a vigorous oxidant and should be used with extreme caution! All potentials were reported versus Ag/AgCl/KCl (3.0 M) reference electrode (BAS Model MF-2078) at room temperature. The electrolyte solutions were degassed with purified nitrogen for 10 min before each experiment and bubbled with nitrogen during the experiment. Operating conditions for SWV were pulse amplitude 25 mV, frequency 15 Hz, potential step 4 mV; and for DPV were pulse amplitude 50 mV, pulse width 50 ms, scan rate 20 mV/s.

Preparation of the standard and quality control solutions

The stock standard solution of bosentan was prepared in 0.1 M TBAClO₄/acetonitrile to a concentration of 100 μg/mL and stored at 4 °C. Working standard solutions were prepared from the stock solution. Standard solutions were prepared as 5-40 μg/mL for LSV and 5-35 μg/mL for SWV and DPV, respectively. The quality control (QC) solutions were prepared by adding aliquots of standard working solution of bosentan to final concentrations of 7.5, 17.5 and 37.5 μg/mL for LSV and 7.5, 17.5 and 32.5 μg/mL for SWV and DPV.

Procedure for pharmaceutical preparations

A total 10 tablets of bosentan (Tracleer and Diamond) accurately weighed and powdered. An amount of this powder corresponding to one tablet bosentan content was weighed and accurately transferred into 100 mL calibrated flask and 50 mL of 0.1 M TBAClO₄/acetonitrile

was added and then the flask was sonicated to 10 min at room temperature. The flask was filled to volume with 0.1 M TBAClO₄/acetonitrile. The resulting solutions in both the cases were filtered through Whatman filter paper no 42 and suitably diluted to get final concentration within the limits of linearity for the respective proposed methods. The drug content of bosentan tablets were calculated from the current potential curves.

Results and Discussion

Voltammetric behavior of bosentan

The electrochemical behavior of bosentan was investigated at the Pt disc electrode in anhydrous acetonitrile solution containing 0.1 M TBAClO₄ as the supporting electrolyte by using cyclic voltammetry (CV). Figure 2 shows a typical cyclic voltammogram of 20 μg/mL bosentan recorded under these conditions for the scan rate of 0.1 V/s. In the anodic sweep, an oxidation peak is seen at about potential of 1.21 V. Upon reversing the potential scan, no reduction peak corresponding to this oxidation wave is observed, indicating the irreversible nature of the electrode reactions.

In order to gain a deeper insight into the voltammetric waves, the effect of scan rate on the anodic peak currents (I_m) and peak potentials (E_p) was studied in the range of 0.01-1 V/s of the potential scan rates in acetonitrile solution containing 20 μg/mL concentration of bosentan (Figure 3). The representative linear sweep voltammograms obtained at Pt electrode for 20 μg/mL bosentan as a function of the scan rate are presented in Figure 4. Scan rate dependency experiments show that the peak currents for peak vary linearly with the scan rate (v) (Figure 4a,b), which points out the adsorption-controlled process. However, the plots of logarithm of peak currents versus logarithm of scan rates for 20 μg/mL concentration of bosentan display straight lines with 0.52 slope (Figure 4c), which are close to theoretical value of 0.5 expected for an ideal diffusion-controlled electrode process (18). Log I_m -log v curve is more eligible for this aim, therefore, a diffusional process for peak should be considered. These results suggest that the redox species are diffusing freely from




Figure 2. Cyclic voltammogram for the oxidation of 20 µg/mL bosentan in acetonitrile containing 0.1 M TBAClO₄ at Pt disk electrode, scan rate: 0.1 V s⁻¹.




Figure 3. Linear sweep voltammograms for the oxidation of 20 µg/mL bosentan in acetonitrile containing 0.1 M TBAClO₄ as a function of scan rate.

solution and not precipitating onto the electrode surface. The reason for this behavior may be due to the solubility of the intermediate species in acetonitrile or poor adherence of products on the electrode surface.

As shown in Figure 3, the oxidation peak potential (E_{pa}) for peaks shift toward more positive values with increasing scan rate. The relationship between the peak potential and scan rate is described by the following equation (19),

$$E_{pa} = E^0 + RT / [(1-\alpha)n_a F] [0.78 + \ln(D^{1/2} k_s^{-1}) - 0.5 \ln RT / [(1-\alpha)n_a F]] + RT / [(1-\alpha)n_a F] / 2 \ln v$$

and from the variation of peak potential with scan rate αn_a can be determined, where α is the transfer coefficient and n_a is the number of electrons transferred in the rate determining step. According to this equation, the plots of the peak potentials versus $\ln v$ for oxidation peak show linear relationship (Figure 5). The slope indicate the value of αn_a is 0.64 for peak. Also, this value obtained indicate the total irreversibility of the electron transfer processes. This result show that the chemical step is a fast following reaction coupled to a charge transfer.

Validation of the method

The validation was carried out by establishing specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), recovery, ruggedness according to ICH Q2B

recommendations (19, 20).

Specificity

The effects of common excipients and additives were tested for their possible interferences in the assay of bosentan. The simulated and placebo samples were prepared and analyzed. It has not been determined any interference of these substances at the levels found in dosage forms. Excipient that was used in this preparation was the most commonly used by the pharmaceutical industry. The presence of titanium dioxide, talc, lactose, starch, and magnesium stearate did not appear interfere in the results of the analysis.

Linearity

Standard solutions were prepared as 5-40 µg/mL (5, 10, 15, 20, 30, 35 and 40) for LSV (Figure 6) and 5-35 µg/mL (5, 10, 15, 20, 25, 30 and 35) for SWV and DPV (Figures 7, 8), respectively. Calibration curves were constructed for bosentan standard by plotting the concentration of compound versus peak current responses. The calibration curves were evaluated by its correlation coefficients. The correlation coefficients (r) of all the calibration curves were consistently greater than 0.99. The linear regression equations were calculated by the least squares method using Microsoft Excel® program and summarized in Table 1.




Figure 4. Dependence of peak current on the scan rate (20 µg/mL).




Figure 5. Dependence of anodic peak potentials of voltammetric peak for the oxidation of 20 µg/mL bosentan on the scan rate.

Accuracy and precision

Accuracy of the assay methods were determined for both intra-day and inter-day variations using the six times analysis of the quality control (QC) samples. Precision of the assay was determined by repeatability (intra-day) and intermediate precision (interday). Repeatability refers to the use of the analytical procedure within a laboratory over a short period of time that was evaluated by assaying the QC samples during the same day. Intermediate precision was assessed by comparing the assays on different days (3 days). The intra-day accuracy ranged from 2.26% to 6.29% and precision from 1.72% to 5.34% (Table 2). The results obtained from intermediate precision (inter-day) also indicated a good method precision. All the values were within the acceptance criteria of 6.29%.

Limits of Detection (LOD) and Quantification (LOQ)

The LOD and LOQ of bosentan by the proposed methods were determined using calibration standards. LOD and LOQ values were calculated as $3.3 \sigma/S$ and $10 \sigma/S$, respectively, where S is the slope of the calibration curve and σ is the standard deviation of y-intercept of regression equation ($n=6$) (21). The LOD and LOQ values of the methods were summarized in Table 1.




Figure 6. a) Linear sweep voltammograms for different concentrations of bosentan in acetonitrile solution containing 0.1 M TBAClO₄ (5, 10, 15, 20, 30, 35 and 40 µ




Figure 7. a) Square wave voltammograms for different concentrations of bosentan in acetonitrile solution containing 0.1 M TBAClO₄ (5, 10, 15, 20, 25, 30 and 35 µ




Figure 8. a) Differential pulse voltammograms for different concentrations of bosentan in acetonitrile solution containing 0.1 M TBAClO₄ (5, 10, 15, 20, 25, 30 and 35 µ

Recovery

To determine the accuracy of the LSV, SWV and DPV methods and to study the interference of formulation additives, the recovery was checked as three different concentration levels. Analytical recovery experiments were performed by adding known amount of pure drugs to pre-analyzed samples of commercial tablet forms. The recovery values were calculated by comparing concentration obtained from the spiked samples with actual added concentrations. These values are also listed in Table 3.

Ruggedness

In this study, the LSV, SWV and DPV determination of bosentan were carried out by a different analyst in same instrument with the same standard (Table 4). The results showed no statistical differences between different operators suggesting that the developed method was rugged.

Stability

To evaluate the stability of bosentan, standard solutions were prepared separately at concentrations covering the low, medium, and higher ranges of calibration curves for different temperature and times. These solutions were stored at room temperature, refrigerated (4 °C) and frozen (-20 °C) temperature for 24 h and 72 h. The stability of bosentan was obtained within the acceptance range of 90-110%.

Comparison of the methods

LSV, SWV and DPV voltammetry methods were applied for the determination of the commercial tablets (Table 3). The results show that high reliability and reproducibility of three methods. The best results were statistically compared using the F-test. At 95% confidence level, the calculated F-values do not exceed the theoretical values (Table 5). Therefore, there are no significant difference between LSV, SWV and DPV voltammetry methods.

The proposed methods were compared with HPLC method (22) in literature. In this study, the concentration of bosentan was determined on a Waters 2695 HPLC system on a reverse phase Agilent XDBC18 column (150 mm × 4.6 mm, *i.d.*, 5 µm) using a mobile phase mixture containing

Table 1. Linearity of bosentan.

Method	Range (µg/mL)	LR	S _a	S _b	R ²	LOD (µg/mL)	LOQ (µg/mL)
LSV	5-40	y=2.9966x+222.65	1.45	0.057	0.9918	1.6	4.8
SWV	5-35	y=1.1357x+66.429	0.31	0.023	0.9934	0.9	2.7
DPV	5-35	y=7.6143x+225.14	0.69	0.068	0.9938	0.3	0.9

^aBased on three calibration curves, LR: linear regression, S_a: standard deviation of intercept of regression line, S_b: Standard deviation of slope of regression line, R²: Coefficient of correlation, y: peak current, x: bosentan concentration, LOD: Limit of detection, LOQ: limit of quantification

Table 2. Precision and accuracy of bosentan.

Method	Intra-day				Inter-day		
	Added (µg/mL)	Found ± SD ^a	Precision % RSD ^b	Accuracy ^c	Found±SD ^a	Precision % RSD ^b	Accuracy ^c
LSV	7.5	7.29 ± 0.19	2.61	-2.80	7.88 ± 0.23	2.91	5.06
	17.5	18.60 ± 0.32	1.72	6.29	18.13 ± 0.30	1.65	3.60
	37.5	35.50 ± 0.79	2.22	-5.33	39.44 ± 0.81	2.05	5.17
SWV	7.5	7.67 ± 0.41	5.34	2.26	7.31 ± 0.31	4.24	-2.53
	17.5	17.95 ± 0.62	3.45	2.57	16.47 ± 0.81	4.92	-5.88
	32.5	31.40 ± 1.39	4.42	-3.38	33.20 ± 1.29	3.89	2.15
DPV	7.5	7.69 ± 0.25	3.25	2.53	7.79 ± 0.34	4.36	3.86
	17.5	16.81 ± 0.71	4.22	-3.94	18.42 ± 0.77	4.18	5.25
	32.5	34.18 ± 0.89	2.60	5.17	33.69 ± 0.65	1.93	3.66

^aSD: Standard deviation of six replicate determinations, ^bRSD: relative standard deviation, Average of six replicate determinations

^cAccuracy: (%relative error) (found-added)/addedx100

Table 3. Recovery of bosentan in pharmaceutical preparations.

Commercial preparation	Method	n	Found (mg) Mean±SD	Recovery	% RSD ^a	Confidence interval
Tracleer (125 mg/tablet)	LSV	6	125.9 ± 2.10	100.7	1.66	123.5- 126.8
	SWV	6	127.3 ± 4.44	101.8	3.48	122.1-129.4
	DPV	6	124.5 ± 1.39	99.6	1.12	121.9-126.7
Diamond (125 mg/tablet)	LSV	6	126.2 ± 3.21	101.0	2.54	124.6-127.4
	SWV	6	127.9 ± 2.53	102.3	1.97	123.9-128.1
	DPV	6	125.7 ± 2.22	100.6	1.76	123.1-127.9

SD: Standard deviation of six replicate determinations, RSD: relative standard deviation, ^aAverage of six replicate determinations

Table 4. The results of analyses of bosentan by a different analyst^a.

Method	Added (µg/mL)	Found (µg/mL) Mean ± SD	% Recovery	% RSD ^a
LSV	5	4.9 ± 0.13	98.0	2.65
	15	14.8 ± 0.27	98.7	1.82
	35	35.4 ± 0.73	101.1	2.06
SWV	5	5.1 ± 0.18	102.0	3.53
	15	14.8 ± 0.25	98.7	1.69
	35	35.2 ± 1.67	100.6	4.74
DPV	5	5.2 ± 0.21	104.0	4.04
	15	14.6 ± 0.28	97.3	1.92
	35	35.6 ± 1.02	101.7	2.87

^aMean measurements of six replicate determinations.

Table 5. Comparison of the proposed and reported methods for determination of bosentan.

Parameters	LSV	SWV	DPV	Reported method [22]
Mean (recovery%)	100.80	101.85	100.85	99.97
SD	2.66	2.49	1.81	0.1051
%RSD	2.64	2.44	1.79	0.1198
Variance	7.08	5.95	3.20	0.0110
F-test	4.02	3.78	3.18	-

SD: Standard deviation of six replicate determinations, RSD: relative standard deviation, Theoretical values at $p=0.05$

H_0 hypothesis: no statistically significant difference exists between four methods

$F_i > F_c$: H_0 hypothesis is accepted ($P > 0.05$)

phosphate buffer (pH 5) and acetonitrile in 45:55% v/v ratio. The flow rate was 1.0 mL/min and column effluents were monitored at 270 nm and bosentan eluted at 5.7 minutes. The method is linear in the concentration range of 25-150 $\mu\text{g/mL}$. In this present work, developed LSV, SWV and DPV methods have small linearity range (5-40 $\mu\text{g/mL}$ for LSV and 5-35 $\mu\text{g/mL}$ for SWV and DPV). As the LOQ of the proposed the methods are lower than the earlier reported works (22, 23).

Besides, the results of the proposed methods were statistically compared with those obtained by the reported method (22). Statistical analysis of the results revealed no significant difference between the performance of the proposed and reference method using variance ratio F test (Table 5). The results obtained showed that the calculated F-values did not exceed the theoretical values from which we can conclude that the proposed method do not differ significantly from HPLC method.

Conclusion

In this study, the electrochemical behavior of bosentan has been studied in nonaqueous media by CV, LSV, SWV and DPV voltammetry methods. It has concluded that there is a completely diffusion-controlled current process which isn't affected by adsorption phenomenon. Besides, in the present report, a simple, rapid, sensitive, reliable, specific, accurate and precise LSV, SWV and DPV methods for the determination of bosentan in pharmaceutical preparations were developed and validated. The method described has been effectively and efficiently used to analyze bosentan pharmaceutical tablets without any interference from the pharmaceutical

excipients. The voltammetric run time of 5 min allows the analysis of a large number of samples in a short period of time. Therefore, the methods can be used effectively without separation for routine analysis of bosentan in pure form and its formulations.

Acknowledgements

This study was supported by a Grant from Ataturk University Research Foundation (Project no: 2012/78).

References

- (1) Clozel M, Breu V, Gray GA, Kalina B, Burri K, Cassal JM, Hirth G, Müller M and Neidhart W. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. *J. Pharmacol. Exp. Ther.* (1994) 270: 228-235.
- (2) Motte S, McEntee K and Naeije R. Endothelin receptor antagonists. *Pharmacol. Ther.* (2006) 110: 386-414.
- (3) Spangler ML and Saxena S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. *Clin. Ther.* (2010) 32: 53-56.
- (4) Atila A, Ozturk M, Kadioglu Y, Halici Z, Turkan D, Yayla M and Un H. Development and validation of UFLC-MS/MS method for determination of bosentan in rat plasma. *J. Pharm. Biomed. Anal.* (2014) 97: 33-38.
- (5) Weber C, Gasser R and Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. *Drug Metab. Dispos.* (1999) 27: 810-815.
- (6) Hoepfer MM, Taha N, Bekjarova A, Gatzke R and Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. *Eur. Respir. J.* (2003) 22: 330-334.
- (7) Hoepfer MM, Kramm T, Wilkens H, Schulze

- C, Schäfers HJ, Welte T and Mayer E. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. *Chest* (2005) 128: 2363-2367.
- (8) McLaughlin VV, Genthner DE, Panella MM and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. *N Engl. J. Med.* (1998) 338: 273-277.
- (9) Votava-Smith JK, Perens GS and Alejos JC. Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt. *Pediatr. Card.* (2007) 28: 314-316.
- (10) Dell D, Lausecker B, Hopfgartner G, Van Giersbergen PLM and Dingemans J. 2002. Evolving bioanalytical methods for the cardiovascular drug bosentan. *Chromatographia* (2002) 55: 115-120.
- (11) Lausecker B, Hess B, Fischer G, Mueller M and Hopfgartner G. Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection. *J. Chromatogr. B* (2000) 749: 67-83.
- (12) Weber C, Gasser R and Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. *Drug Metab. Dispos.* (1999) 27: 810-815.
- (13) Muralidharan S and Kumar JR. Simple estimation of bosentan in tablet formulation by RP-HPLC. *American J. Anal. Chem.* (2012) 3: 715-718.
- (14) El-Hefnawy GB, El-Hallag IS, Ghoneim EM and Ghoneim MM. Voltammetric behavior and quantification of the sedative-hypnotic drug chlorthalidopoxide in bulk form, pharmaceutical formulation and human serum at a mercury electrode. *J. Pharm. Biomed. Anal.* (2004) 34: 75-86.
- (15) Corti P, Corbini G, Gratteri P, Furlanetto S and Pinzauti S. Determination of some quinolones in tablets, human plasma and urine by differential-pulse polarography. *Int. J. Pharm.* (1994) 111: 83-87.
- (16) Radi A and Elmogy T. Differential pulse voltammetric determination of carvedilol in tablets dosage form using glassy carbon electrode. *Farmaco* (2005) 60: 43-46.
- (17) Dogan B and Ozkan SA. Electrochemical Behavior of Carvedilol and its Adsorptive stripping determination in dosage forms and biological fluids. *Electroanalysis* (2005) 17: 2074-2083.
- (18) Laviron E, Roullier L and Degrand C. A multilayer model for the study of space distributed redox modified electrodes: Part II. Theory and application of linear potential sweep voltammetry for a simple reaction. *J. Electroanal. Chem.* (1980) 112: 11-23.
- (19) Yilmaz B and Ekinci D. Voltammetric behavior of carvedilol in non-aqueous media and its analytical determination in pharmaceutical preparations. *Rev. Anal. Chem.* (2011) 30: 187-193.
- (20) Guidance for Industry Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD (2001).
- (21) The European Agency for the Evaluation of Medicinal Products. ICH Topic Q2B Note for Guideline on Validation of Analytical Procedures: Methodology GPMP/ICH/281/95 (1996).
- (22) Kalaichelvi R and Jayachandran E. Estimation of bosentan in pure and tablet dosage form by RP-HPLC. *Int. J. Pharm. Chem. Sci.* (2013) 2: 837-840.
- (23) Kumar AA and Sankar DG. Development, estimation and validation of bosentan in bulk in its pharmaceutical formulation by UV-VIS spectroscopic method. *Int. J. Pharm. Bio. Sci.* (2011) 2: 225-230.

This article is available online at <http://www.ijpr.ir>

**Search full text articles?
Visit <http://www.ijpr.ir>
or
[http:// ijpr.sbm.ac.ir](http://ijpr.sbm.ac.ir)**